Results of cryopreserved arterial allograft replacement for thoracic and thoracoabdominal aortic infections
Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Primary and secondary thoracic aortic infections are rare but associated with high morbidity and mortality. There is currently no consensus on their optimal treatment. Arterial allografts have been shown to be resistant to bacterial colonization. Complete excision of infected material, especially synthetic grafts, combined with in situ aortic repair is considered the best treatment of abdominal aortic infections. The aim of this study was to assess the management of thoracic and thoracoabdominal aortic infections using arterial allografts.
METHODS: Between January 2009 and December 2017, all patients with thoracic and thoracoabdominal aortic native or graft infections underwent complete excision of infected material and in situ arterial allografting. The end points were the early mortality and morbidity rates and early and late rates of reinfection, graft degeneration, and graft-related morbidity.
RESULTS: Thirty-five patients with a mean age of 65.6 ± 9.2 years were included. Twenty-one (60%) cases experienced graft infections and 14 (40%) experienced native aortic infections. Eight (22.8%) patients had visceral fistulas: 5 (14.4%) prosthetic-esophageal, 1 (2.8%) prosthetic-bronchial, 1 (2.8%) prosthetic-duodenal, and 1 (2.8%) native aortobronchial. In 12 (34.3%) cases, only the descending thoracic aorta was involved; in 23 (65.7%) cases, the thoracoabdominal aorta was involved. Fifteen (42.8%) patients died during the first month or before discharge: 5 of hemorrhage, 4 of multiorgan failure, 3 of ischemic colitis, 2 of pneumonia, and 1 of anastomotic disruption. Eleven (31.5%) patients required early revision surgery: 6 (17.1%) for nongraft-related hemorrhage, 3 (8.6%) for colectomy, 1 (2.9%) for proximal anastomotic disruption, and 1 (2.9%) for tamponade. One (2.9%) patient who died before discharge experienced paraplegia. One (2.9%) patient experienced stroke. Six (17.1%) patients required postoperative dialysis. Among them, four died before discharge. The mean length of stay in the intensive care unit was 11 ± 10.5 days; the mean length of hospital stay was 32 ± 14 days. During a mean follow-up of 32.3 ± 23.7 months, three allograft-related complications occurred in survivors (15% of late survivors): one proximal and one distal false aneurysm with no evidence of reinfection and one allograft-enteric fistula. The 1-year and 2-year survival rates were 49.3% and 42.5%, respectively.
CONCLUSIONS: Although rare, aortic infections are highly challenging. Surgical management includes complete excision of infected tissues or grafts. Allografts offer a promising solution to aortic graft infection because they appear to resist reinfection; however, the grafts must be observed indefinitely because of the risk of late graft complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Journal of vascular surgery - 73(2021), 2 vom: 30. Feb., Seite 626-634 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Couture, Thibault [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cryopreserved arterial allograft |
|---|
| Anmerkungen: |
Date Completed 30.08.2021 Date Revised 30.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jvs.2020.05.052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320476650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320476650 | ||
| 003 | DE-627 | ||
| 005 | 20231225173651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvs.2020.05.052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320476650 | ||
| 035 | |a (NLM)33485491 | ||
| 035 | |a (PII)S0741-5214(20)31308-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Couture, Thibault |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Results of cryopreserved arterial allograft replacement for thoracic and thoracoabdominal aortic infections |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2021 | ||
| 500 | |a Date Revised 30.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Primary and secondary thoracic aortic infections are rare but associated with high morbidity and mortality. There is currently no consensus on their optimal treatment. Arterial allografts have been shown to be resistant to bacterial colonization. Complete excision of infected material, especially synthetic grafts, combined with in situ aortic repair is considered the best treatment of abdominal aortic infections. The aim of this study was to assess the management of thoracic and thoracoabdominal aortic infections using arterial allografts | ||
| 520 | |a METHODS: Between January 2009 and December 2017, all patients with thoracic and thoracoabdominal aortic native or graft infections underwent complete excision of infected material and in situ arterial allografting. The end points were the early mortality and morbidity rates and early and late rates of reinfection, graft degeneration, and graft-related morbidity | ||
| 520 | |a RESULTS: Thirty-five patients with a mean age of 65.6 ± 9.2 years were included. Twenty-one (60%) cases experienced graft infections and 14 (40%) experienced native aortic infections. Eight (22.8%) patients had visceral fistulas: 5 (14.4%) prosthetic-esophageal, 1 (2.8%) prosthetic-bronchial, 1 (2.8%) prosthetic-duodenal, and 1 (2.8%) native aortobronchial. In 12 (34.3%) cases, only the descending thoracic aorta was involved; in 23 (65.7%) cases, the thoracoabdominal aorta was involved. Fifteen (42.8%) patients died during the first month or before discharge: 5 of hemorrhage, 4 of multiorgan failure, 3 of ischemic colitis, 2 of pneumonia, and 1 of anastomotic disruption. Eleven (31.5%) patients required early revision surgery: 6 (17.1%) for nongraft-related hemorrhage, 3 (8.6%) for colectomy, 1 (2.9%) for proximal anastomotic disruption, and 1 (2.9%) for tamponade. One (2.9%) patient who died before discharge experienced paraplegia. One (2.9%) patient experienced stroke. Six (17.1%) patients required postoperative dialysis. Among them, four died before discharge. The mean length of stay in the intensive care unit was 11 ± 10.5 days; the mean length of hospital stay was 32 ± 14 days. During a mean follow-up of 32.3 ± 23.7 months, three allograft-related complications occurred in survivors (15% of late survivors): one proximal and one distal false aneurysm with no evidence of reinfection and one allograft-enteric fistula. The 1-year and 2-year survival rates were 49.3% and 42.5%, respectively | ||
| 520 | |a CONCLUSIONS: Although rare, aortic infections are highly challenging. Surgical management includes complete excision of infected tissues or grafts. Allografts offer a promising solution to aortic graft infection because they appear to resist reinfection; however, the grafts must be observed indefinitely because of the risk of late graft complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cryopreserved arterial allograft | |
| 650 | 4 | |a Thoracic aortic infection | |
| 650 | 4 | |a Thoracoabdominal aortic infection | |
| 700 | 1 | |a Gaudric, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Davaine, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Jayet, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Chiche, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Jarraya, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Koskas, Fabien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of vascular surgery |d 1988 |g 73(2021), 2 vom: 30. Feb., Seite 626-634 |w (DE-627)NLM012713147 |x 1097-6809 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:2 |g day:30 |g month:02 |g pages:626-634 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvs.2020.05.052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 2 |b 30 |c 02 |h 626-634 | ||